Evotec Invests €15m In AI-driven Exscientia
Executive Summary
Evotec has deepened its relationship with artificial intelligence company Exscientia by investing €15m in the UK-based company; the CRO wants to build on the pair's existing collaboration in immuno-oncology and use its stake to diversify the AI firm's portfolio.
You may also be interested in...
Exscientia Bags Roche As AI Partner And $26m Series B To Fund Own Pipeline
Exscientia's top executives tell Scrip why Roche opted for its AI insights - and how the UK group will use a $26m series B financing to build its proprietary pipeline.
Another Big Pharma Embraces AI As Exscientia Bags GSK
GSK's deal with Exscientia will see the Scottish artificial intelligence pioneer discover new small molecules against targets selected by the big pharma. Exscientia is already working with Sanofi, Evotec, Sumitomo Dainippon Pharma and Sunovion across a range of disease areas, and is in talks with others.
Quest To Use AI In Drug Discovery Joins Sanofi and Exscientia
Sanofi hopes to use Exscientia's artificial intelligence (AI) platform to develop bispecific-small-molecule drugs for diabetes and associated metabolic conditions.